Kiniksa Pharmaceuticals, Ltd. provided earnings guidance for the full-year 2022. For the year, the company expects ARCALYST net revenue for the full-year 2022 to be between $115 million and $130 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.46 USD | -1.09% | -0.10% | +10.95% |
May. 14 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.95% | 1.4B | |
+8.26% | 115B | |
+13.00% | 107B | |
-13.57% | 22.31B | |
-3.99% | 21.6B | |
-5.79% | 18.23B | |
-39.93% | 17.62B | |
+7.35% | 14.26B | |
+33.49% | 12.37B | |
-28.19% | 8.28B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Earnings Guidance for the Full-Year 2022